How much does a box of Acemini cost? A complete guide to import prices and medical insurance reimbursement in 2025

Asciminib is a new type of targeted drug mainly used to treat chronic myeloid leukemia (CML), especially for patients who are resistant to traditional tyrosine kinase inhibitors (TKIs) such as imatinib. Due to the outstanding efficacy of aceminib, it has gradually become one of the important treatment options in the treatment of CML. However, the price of Aceminid in the global market, import fees and medical insurance policy issues have always been the focus of patients. This article will provide a comprehensive analysis of the import price and medical insurance reimbursement status of Aceminib in 2025 to help patients understand the cost burden of the drug and related policies.

First of all, Asiminib has not yet been launched in the Chinese market, which means that patients cannot purchase it through official domestic channels, nor can they obtain drug reimbursement through the medical insurance system. Therefore, if domestic patients need to use Asiminib, they can only purchase it through overseas channels. According to the current sales situation in overseas markets, the common specifications of the European version of Aceminid’s original drug are 40mg × 60 tablets, and the price per box is about 40,000 yuan. Prices may fluctuate due to factors such as exchange rate changes, tariffs, and shipping charges. In addition, patients also need to pay corresponding international logistics costs and possible import duties when purchasing through overseas channels.

In addition to the original drug, there are also some generic drugs of Aceminid on the market, mainly produced by some international pharmaceutical companies. For example, the generic drug of Asiminib produced by the Lucius Pharmaceutical Factory in Laos is 40 mg × 60 tablets. The price per box is about more than 2,000 yuan, which is significantly lower than the price of the original drug. Although generic drugs are more affordable, it should be noted that there may be differences in quality, production standards, and regulatory measures between generic drugs and original drugs. Therefore, patients should weigh the balance between price and drug quality when choosing to ensure the efficacy and safety of the drug.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib